Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2Enrolling by invitation 1

Sponsor Class

NIH 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Classical hematology 10Myeloid 5Other hematologic neoplasm 3Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 394Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Hematologic Neoplasms 206Leukemia, Lymphocytic, Chronic, B-Cell 175Myelodysplastic Syndromes 144Leukemia 125Lymphoma 90Lymphoma, Non-Hodgkin 76Multiple Myeloma 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Recurrence 55Neoplasms 53Leukemia, Myelomonocytic, Chronic 50Burkitt Lymphoma 44Lymphoma, Large B-Cell, Diffuse 41Leukemia, Biphenotypic, Acute 41Myeloproliferative Disorders 39Lymphoma, Mantle-Cell 39Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 37Hodgkin Disease 36Lymphoma, B-Cell 32Lymphoma, Follicular 31Leukemia, B-Cell 27Lymphoma, B-Cell, Marginal Zone 24Anemia, Refractory, with Excess of Blasts 24Waldenstrom Macroglobulinemia 23Primary Myelofibrosis 21Myelodysplastic-Myeloproliferative Diseases 20Hematologic Diseases 19Lymphoma, T-Cell 16

Interventions

ibrutinib 1fludarabine phosphate 1Rituximab 1Pharmacogenomic Testing 1Lenalidomide 1Epoetin Alfa 1Cyclophosphamide 1CT-P10 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Anemia × Other hematologic neoplasm × 90 days × Clear all
NCT00001620 2026-05-29

Screening for Hematology Branch Protocols

National Institutes of Health Clinical Center (CC)

Enrolling by invitation
10,000 enrolled
Classical hematologyOther hematologic neoplasm

Cytopenia, Anemia, Disease, Hematologic Diseases, Neutropenia, Thrombocytopenia, Hematologic Neoplasms

NCT00843882 2026-05-29

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
247 enrolled 19 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡